Bioarray logo 203

BIOARRAY Genetics, Inc.

Revolutionizing cancer treatment decisions with patient-specific precision tests.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Farmington, CT, US
  • Currency USD
  • Founded December 2009
  • Employees 5
  • Incorporation Type C-corp
  • Website bioarray.us

Company Summary

BIOARRAY Genetics is a molecular diagnostics company focused on changing the way in which cancer patients are evaluated and treated. The Company’s panel of over 300 unique genes and proprietary algorithms serve as the foundation for the development tests that predict patient response to cancer treatments, as well as a template for companion diagnostics. The Company’s lead test (BA100), an RNA-based predictive test, identifies those women diagnosed with stage I-III breast cancer who will not realize a complete response to the traditional first-line of pre and post-surgical chemotherapy. Presently, approximately 76% of the 155,000 breast cancer patients who undergo the standard-of-care chemotherapy do not completely respond to the treatment, costing the U.S healthcare system $2.59 billion annually. BA100 is able to identify responders and non-responders to reduce ineffective chemotherapy treatments by 55% and increase treatment response by 68%. There are presently no tests available that provide the vital information generated by BA100 resulting in a large unmet medical need with a market opportunity in the US of $542M.


  • Default avatar
    Marcia Fournier
    CEO, Board director

    Precision medicine is what inspired Marcia Fournier to start BIOARRAY. Marcia has over 15 years experience in oncology, drug discovery, biomarkers, and clinical diagnostics. Prior to founding BIOARRAY, Marcia held positions in top Institutions in the US including GlaxoSmithKline, UC Berkeley and Dana-Farber Cancer Institute. Marcia holds a PhD in molecular biology from Federal University of Rio de Janeiro.

  • Default avatar
    Pamela Layton
    President Executive Chairman

    Pamela Layton, is a serial entrepreneur with expertise in biologics and diagnostics. Prior to joining BIOARRAY Pamela was founder and CEO of the Parcell Group, taking one of the first pure stem cell products from bench to bedside for spinal fusion surgeries. She holds multiple U.S. and European patents. She serves as member and advisor to multiple innovation organizations including MIT, SBANE Innovation Awards, Launchpad Ventures.

  • Default avatar
    Jim LaFrance
    Board of Directors

    Jim LaFrance, a member of the Board of Directors, is Chairman of the Board of Vermillion (VRML) Inc., and on the Board of publicly traded High Throughput Genomics (HTGM), a next generation sequencing RNA profiling company. Mr. LaFrance has held positions as CEO of Vermillion and Omnyx, a GE Healthcare JV with UPMC. He has also held executive leadership roles at Ventana Medical Systems (acquired by Roche Diagnostics) and Bayer Diagnostics.

  • Default avatar
    Michal Preminger
    Board Member

    Michal is a serial entrepreneur in life sciences, current Executive Director Office of Tech Dev Harvard Medical School. Prior to joining Harvard in 2005, she held a number of positions in R&D and Business Development at Compugen, most recently as VP of Protein Therapeutics, responsible for the business management of the company's emerging drug discovery pipeline. She has a PhD from the Weizmann Institute of Science, and MBA from INSEAD in France.

  • Default avatar
    Don Hardison
    Board of Advisors

    Don Hardison, a leader in the diagnostics industry, was most recently the President and CEO of Good Start Genetics. Previously he held a number of executive and senior management positions at companies including Laboratory Corporation of America (COO), Exact Sciences (CEO), OnTarget, Inc., Quest Diagnostics Inc. and SmithKline Beecham. He currently sits on the board of HTG Molecular Diagnostics, IQuity, Seventh Sense and BioTheranostics.

  • 89f7b47c 651a 4d2e 9b2e 47855ab14c93
    Board of Advisors

    Dr. Witney most recently served as President and CEO of Affymetrix, Inc. and engineered the sale of the company to Thermo Fisher. Previous positions include CEO of Dionex Corp., President of Panomics Inc., President of PerkinElmer’s Drug Discovery Tools division and COO/President of Packard BioScience. He is currently Chairman of the Board of Gyros Protein Technologies and holds Board positions for Cerus Corp., Exagen Diagnostics and Rarecyte.


  • Default avatar
    Dr. Susan Tannenbaum, a leading breast oncologist and the Chief of Hematology and Oncology at UCONN Health Center, trained at UPenn for her fellowship in hematology-oncology followed by 9 years at the NIH. Focal interest survivorship and quality of life.
    Default avatar
    Dr. Mauricio Costa, one of the leading breast oncologists in Latin America, is noted for his publications on breast cancer treatment and the reduction of breast cancer in Latin America. He is the past President of the Latin American Breast Cancer Society

Previous Investors

  • Default avatar
    Avon Foundation for Women
    Default avatar
    Connecticut Innovations